Biotech & AI drug discoverySTAT — Biotech

STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer

A Phase 3 trial involving a targeted drug developed by Merck and Kelun-Biotech showed that it reduced the risk of death by one-third in patients with advanced endometrial cancer.

AI summary · generated only from source feed metadata; consult original

Source published2026-10-26T15:30:00+00:00

Published here2026-10-26T17:00:08+00:00

Original source

STAT — Biotech

Media report · consult original reporting

Read the original ↗https://www.statnews.com/2026/10/26/merck-kelun-sac-tmt-endometrial-cancer-study-esmo-2026/

Original headline

STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer

AI bilingual edit · consult original

Headlines are indexed or machine translated, not independent verification of scientific results. Medical news is not clinical advice. Distinguish interstellar concepts from demonstrated space technology using the original source.